It has been well known that several neuropeptides may affect human behavior, and that some endocrinopathies are associated with impaired higher function of the brain. The major outcomes suggest that patients with GADA-positive diabetes are at a higher risk of cognitive decline than patients with type 2 diabetes. History of SH associated with lower cognitive function and steeper estimated lifetime decline (fully adjusted analyses). Data on peritoneal dialysis patients were insufficient for a meaningful comparison. To further investigate the impact of type 2 diabetes on cognition, the correlation of ALFF and the neuropsychological tests for the MCI-DM and MCI group were calculated. Participants with diabetes (n=126) had worse cognitive performance than participants who did not have diabetes (n=1,228; adjusted odds ratio 1.51 [95% CI 1.03-2.21]). CONCLUSIONS In diabetic people with HbA1c >7.5% at high risk for cardiovascular disease, decreased cognitive function was associated with kidney disease as measured by ACR, a measure of microvascular endothelial pathology, and cystatin C, a marker of eGFR.
These findings show that PVT1-mediated autophagy may protect hippocampal neurons from impairment of synaptic plasticity and apoptosis, and then ameliorates cognitive impairment in diabetes. Covariates included demographics, body mass index, smoking, alcohol consumption, physical exercise and medical conditions. According to the article, the two health outcomes were closely linked. Participants’ medical records were used to determine whether they had Type 2 diabetes. Children may be more prone to acute metabolic insults, and there is evidence of developmental disadvantage associated with hypoglycaemic episodes.